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A-fi b and rate control: 
Don’t go too low
For patients with atrial fi brillation, more relaxed heart 
rate control is as eff ective as stricter control—with fewer 
adverse eff ects. 
PRACTICE CHANGER
Aim for a heart rate of <110 beats per minute 
(bpm) in patients with permanent atrial fi -
brillation. Maintaining this rate requires less 
medication than more stringent rate con-
trol, resulting in fewer side eff ects and no in-
creased risk of cardiovascular events.1
STRENGTH OF RECOMMENDATION
B: Based on 1 long-term randomized con-
trolled trial (RCT).
Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict 
rate control in patients with atrial fi brillation. N Engl J Med. 2010;362:
1363-1373. 
 ILLUSTRATIVE CASE
A 67-year-old man comes in for a follow-up 
visit after being hospitalized for atrial fi brilla-
tion with a rapid ventricular rate. Before be-
ing discharged, he was put on warfarin and 
metoprolol, and his heart rate today is 96 bpm. 
You consider increasing the dose of his beta-
blocker. What should his target heart rate be?
A trial fi brillation, the most common sustained arrhythmia,2 can lead to life-threatening events such as 
heart failure and stroke. Studies, including 
the Atrial Fibrillation Follow-Up Investiga-
tion of Rhythm Management (AFFIRM) and 
Rate Control versus Electrical Cardioversion 
(RACE) trials, have found no diff erence in 
morbidity or mortality between rate control 
and rhythm control strategies.2,3 Th us, rate 
control is usually preferred for patients with 
atrial fi brillation because of adverse eff ects 
associated with antiarrhythmic drugs. 
Guidelines cite stringent targets 
Th e American College of Cardiology/Ameri-
can Heart Association Task Force/Europe-
an Society of Cardiology (ACC/AHA/ESC) 
guidelines make no defi nite recommenda-
tions about heart rate targets. Th e guidelines 
do indicate, however, that rate control crite-
ria vary based on age, “but usually involve 
achieving ventricular rates between 60 and 80 
[bpm] at rest and between 90 and 115 [bpm] 
during moderate exercise.”4
Th is guidance is based on data from 
epidemiologic studies suggesting that faster 
heart rates in sinus rhythm may increase 
mortality from cardiovascular causes.5 How-
ever, strict control often requires higher doses 
of rate-controlling medications, which can 
lead to adverse events such as symptomatic 
bradycardia, dizziness, and syncope, as well 
as pacemaker implantation. 
Pooled data suggest a more 
relaxed rate is better
A retrospective analysis of pooled data from 
the rate-control arms of the AFFIRM and 
RACE trials found no diff erence in all-cause 
mortality between the more stringent rate-
control group in AFFIRM and the more le-
nient control in RACE.6 Th is fi nding suggested 
that more lenient heart rate targets may be 
preferred to avoid the adverse eff ects often 
associated with the higher doses of rate-
controlling drugs needed to achieve strict con-
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The lenient-control group 
had fewer visits for rate 
control, required fewer 
medications, and took 
lower doses of some 
medications. 
bination as needed to reach the target heart 
rate. In both groups, the resting heart rate was 
determined by 12-lead electrocardiogram after 
the patient remained in a supine position for 2 
to 3 minutes. In the strict-control group, heart 
rate was also measured during moderate exer-
cise on a stationary bicycle after the resting rate 
goal had been achieved. In addition, patients in 
the strict-control group wore a Holter monitor 
for 24 hours to check for bradycardia. 
Participants in both groups were seen 
every 2 weeks until their heart rate goals were 
achieved, with follow-up at 1, 2, and 3 years. Th e 
primary composite outcome included death 
from cardiovascular causes; hospitalization for 
heart failure, stroke, systemic embolism, major 
bleeding, or life-threatening adverse eff ects of 
rate-control drugs; arrhythmic events, includ-
ing sustained ventricular tachycardia, syncope, 
or cardiac arrest; and implantation of a pace-
maker or cardioverter-defi brillator.
❚ At the end of 3 years, the estimated 
cumulative incidence of the primary outcome 
was 12.9% in the lenient-control group vs 14.9% 
in the strict-control group. Th e absolute diff er-
ence was -2.0 (90% confi dence interval [CI], 
-7.6 to 3.5); a 90% CI was acceptable because 
trol. Th e Rate Control Effi  cacy in Permanent 
Atrial Fibrillation: a Comparison between Le-
nient versus Strict Rate Control II (RACE II) 
study we report on here provides strong evi-
dence in favor of lenient rate control.
STUDY SUMMARY
Lenient control is as effective, 
easier to achieve
RACE II was the fi rst RCT to directly com-
pare lenient rate control (resting heart rate 
<110 bpm) with strict rate control (resting 
heart rate <80 bpm, and <110 bpm during 
moderate exercise). Th is prospective, multi-
center study in Holland randomized patients 
with permanent atrial fi brillation (N=614) to 
either a lenient or strict rate-control group. 
Eligibility criteria were (1) permanent atrial fi -
brillation for up to 12 months; (2) ≤80 years of 
age (3) mean resting heart rate >80 bpm; and 
(4) current use of oral anticoagulation therapy 
(or aspirin, in the absence of risk factors for 
thromboembolic complications). 
Patients received various doses of 
beta-blockers, nondihydropyridine calcium-
channel blockers, or digoxin, singly or in com-
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the study only tested whether lenient control 
was worse than strict control. Th e frequency 
of reported symptoms and adverse events was 
similar between the 2 groups, but the lenient-
control group had fewer visits for rate control 
(75 vs 684; P<.001), required fewer medications, 
and took lower doses of some medications. 
Heart rate targets were met in 97.7% of 
patients in the lenient-control group, com-
pared with 67% in the strict-control group 
(P<.001). Of those not meeting the strict 
control targets, 25% were due to an adverse 
medication event. Th ere were no diff erences 
between the 2 groups in symptoms or in New 
York Heart Association functional class status. 
WHAT’S NEW
Now we know: It doesn’t pay 
to go too low
A heart rate <80 at rest and <110 during exer-
cise is diffi  cult to maintain. Th is more stringent 
target often requires high dosages of drugs 
and/or multiple medications, which may lead 
to adverse eff ects. Th is RCT—the fi rst to com-
pare outcomes in patients with lenient vs strict 
heart rate control—found that morbidity and 
mortality were similar between the 2 groups. 
Th is means that, in many cases, patients will 
need less medication—leading to a reduction 
in risk of side eff ects and interactions. 
CAVEATS
Unblinded study excluded 
very old, high risk
Th is was not a blinded study, so both patients 
and providers knew the target heart rates. 
However, the major outcomes were deter-
mined with relative objectivity and were not 
diff erent between the 2 groups, so it is un-
likely that this knowledge would have a ma-
jor eff ect on the results. Nonetheless, this is a 
single study, and the fi ndings are not yet sup-
ported by other large, prospective studies.
Th e researchers did not enroll patients 
>80 years, who have a higher incidence of 
atrial fi brillation and are less likely than 
younger patients to tolerate higher doses 
of rate-controlling medications. Also ex-
cluded were sedentary patients and those 
with a history of stroke, which resulted in a 
lower-risk study population. However, 40% 
of the subjects had a CHADS score ≥2 (an 
indication of high risk of stroke in patients 
with atrial fi brillation), and subgroup analy-
sis found that the results applied to higher-
risk groups.
Finally, it is possible that it may take lon-
ger than 3 years (the duration of study follow-
up) for higher ventricular rates to result in 
adverse cardiovascular outcomes and that 
there could be a benefi t of strict rate control 
over a longer period of time.
CHALLENGES TO IMPLEMENTATION
Guidelines do not refl ect 
these fi ndings
Th ese fi ndings are not yet incorporated into 
the ACC/AHA/ESC guidelines or those issued 
by other organizations. Clinical inertia may 
stop some physicians from reducing medica-
tions for patients with atrial fi brillation, but 
in general, both doctors and patients should 
welcome an easing of the drug burden.       JFP
Virtually all 
(97.7%) of the 
patients in the 
lenient-control 
group reached 
their target heart 
rate, 
compared with 
67% of those 
in the strict-
control group. 
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